The Future of Drug Development in Urothelial Cancer

被引：6

作者：

Dreicer, Robert ^{[1
]}

机构：

[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期

关键词：

TRANSITIONAL CELL-CARCINOMA; BLADDER-CANCER; ONCOLOGY-GROUP; GENE AMPLIFICATION; CHEMOTHERAPY; CISPLATIN; THERAPY; TRIAL; OVEREXPRESSION; METHOTREXATE;

D O I：

10.1200/JCO.2011.39.5566

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：473 / 475

页数：4

共 16 条

[1] I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy [J].

Barker, A. D. ;

Sigman, C. C. ;

Kelloff, G. J. ;

Hylton, N. M. ;

Berry, D. A. ;

Esserman, L. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) :97-100

[2] No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas [J].

Caner, Vildan ;

Sen Turk, Nilay ;

Duzcan, Fusun ;

Tufan, N. Lale Satiroglu ;

Kelten, E. Canan ;

Zencir, Sevil ;

Dodurga, Yavuz ;

Bagci, Huseyin ;

Duzcan, S. Ender .

PATHOLOGY & ONCOLOGY RESEARCH, 2008, 14 (03) :261-266

[3] Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group [J].

Chakravarti, A ;

Winter, K ;

Wu, CL ;

Kaufman, D ;

Hammond, E ;

Parliament, M ;

Tester, WL ;

Hagan, M ;

Grignon, D ;

Heney, N ;

Pollack, A ;

Sandler, H ;

Shipley, W .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02) :309-317

[4] Bladder cancer: translating molecular genetic insights into clinical practice [J].

Cheng, Liang ;

Zhang, Shaobo ;

MacLennan, Gregory T. ;

Williamson, Sean R. ;

Lopez-Beltran, Antonio ;

Montironi, Rodolfo .

HUMAN PATHOLOGY, 2011, 42 (04) :455-481

[5] Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer [J].

Choueiri, Toni K. ;

Ross, Robert W. ;

Jacobus, Susanna ;

Vaishampayan, Ulka ;

Yu, Evan Y. ;

Quinn, David I. ;

Hahn, Noah M. ;

Hutson, Thomas E. ;

Sonpavde, Guru ;

Morrissey, Stephanie C. ;

Buckle, Geoffrey C. ;

Kim, William Y. ;

Petrylak, Daniel P. ;

Ryan, Christopher W. ;

Eisenberger, Mario A. ;

Mortazavi, Amir ;

Bubley, Glenn J. ;

Taplin, Mary-Ellen ;

Rosenberg, Jonathan E. ;

Kantoff, Philip W. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :507-512

[6] Systemic chemotherapy for advanced bladder cancer: Update and controversies [J].

Garcia, Jorge A. ;

Dreicer, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) :5545-5551

[7] Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75 [J].

Hahn, Noah M. ;

Stadler, Walter M. ;

Zon, Robin T. ;

Waterhouse, David ;

Picus, Joel ;

Nattam, Sreenivasa ;

Johnson, Cynthia S. ;

Perkins, Susan M. ;

Waddell, Mary Jane ;

Sweeney, Christopher J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1525-1530

[8] CISPLATIN, METHOTREXATE, AND VINBLASTINE (CMV) - AN EFFECTIVE CHEMOTHERAPY REGIMEN FOR METASTATIC TRANSITIONAL CELL-CARCINOMA OF THE URINARY-TRACT - A NORTHERN-CALIFORNIA-ONCOLOGY-GROUP STUDY [J].

HARKER, WG ;

MEYERS, FJ ;

FREIHA, FS ;

PALMER, JM ;

SHORTLIFFE, LD ;

HANNIGAN, JF ;

MCWHIRTER, KM ;

TORTI, FM .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (11) :1463-1470

[9] Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial [J].

Hussain, Maha H. A. ;

MacVicar, Gary R. ;

Petrylak, Daniel P. ;

Dunn, Rodney L. ;

Vaishampayan, Ulka ;

Lara, Primo N., Jr. ;

Chatta, Gurkamal S. ;

Nanus, David M. ;

Glode, L. Michael ;

Trump, Donald L. ;

Chen, Helen ;

Smith, David C. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) :2218-2224

[10]

Iyer G, 2010, EXPERT REV ANTICANC, V10, P1917, DOI [10.1586/era.10.182, 10.1586/ERA.10.182]

← 1 2 →